82 related articles for article (PubMed ID: 8797539)
21. Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease.
Pang CP; Zhang J; Woo J; Chan D; Law LK; Tong SF; Kwok T; Kay R
Mov Disord; 1998 May; 13(3):529-32. PubMed ID: 9613747
[TBL] [Abstract][Full Text] [Related]
22. A susceptibility locus for Parkinson's disease maps to chromosome 2p13.
Gasser T; Müller-Myhsok B; Wszolek ZK; Oehlmann R; Calne DB; Bonifati V; Bereznai B; Fabrizio E; Vieregge P; Horstmann RD
Nat Genet; 1998 Mar; 18(3):262-5. PubMed ID: 9500549
[TBL] [Abstract][Full Text] [Related]
23. A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females.
Lin JJ; Chen CH; Yueh KC; Chang CY; Lin SZ
Parkinsonism Relat Disord; 2006 Jan; 12(1):9-13. PubMed ID: 16337421
[TBL] [Abstract][Full Text] [Related]
24. Mitochondrial transcription factor A (TFAM) gene variation in Parkinson's disease.
Alvarez V; Corao AI; Sánchez-Ferrero E; De Mena L; Alonso-Montes C; Huerta C; Blázquez M; Ribacoba R; Guisasola LM; Salvador C; García-Castro M; Coto E
Neurosci Lett; 2008 Feb; 432(1):79-82. PubMed ID: 18248889
[TBL] [Abstract][Full Text] [Related]
25. Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population.
Huerta C; Castro MG; Coto E; Blázquez M; Ribacoba R; Guisasola LM; Salvador C; Martínez C; Lahoz CH; Alvarez V
J Neurol Sci; 2005 Sep; 236(1-2):49-54. PubMed ID: 15975594
[TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease.
Feldman B; Chapman J; Korczyn AD
Acta Neurol Scand; 2006 Jan; 113(1):14-7. PubMed ID: 16367893
[TBL] [Abstract][Full Text] [Related]
27. Association between the estrogen receptor beta gene and age of onset of Parkinson's disease.
Westberg L; Håkansson A; Melke J; Shahabi HN; Nilsson S; Buervenich S; Carmine A; Ahlberg J; Grundell MB; Schulhof B; Klingborg K; Holmberg B; Sydow O; Olson L; Johnels EB; Eriksson E; Nissbrandt H
Psychoneuroendocrinology; 2004 Sep; 29(8):993-8. PubMed ID: 15219649
[TBL] [Abstract][Full Text] [Related]
28. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
[TBL] [Abstract][Full Text] [Related]
29. Genetic variants of the PITX3 gene are not associated with late-onset sporadic Parkinson's disease in a Chinese population.
Cai Y; Ding H; Gu Z; Ma J; Chan P
Neurosci Lett; 2011 Jul; 498(2):124-6. PubMed ID: 21565251
[TBL] [Abstract][Full Text] [Related]
30. CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia.
Gołab-Janowska M; Honczarenko K; Gawrońska-Szklarz B; Potemkowski A
Neurol Neurochir Pol; 2007; 41(2):113-21. PubMed ID: 17530572
[TBL] [Abstract][Full Text] [Related]
31. Lack of evidence for a genetic association between FGF20 and Parkinson's disease in Finnish and Greek patients.
Clarimon J; Xiromerisiou G; Eerola J; Gourbali V; Hellström O; Dardiotis E; Peuralinna T; Papadimitriou A; Hadjigeorgiou GM; Tienari PJ; Singleton AB
BMC Neurol; 2005 Jun; 5():11. PubMed ID: 15967032
[TBL] [Abstract][Full Text] [Related]
32. Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study.
Taylor CA; Saint-Hilaire MH; Cupples LA; Thomas CA; Burchard AE; Feldman RG; Myers RH
Am J Med Genet; 1999 Dec; 88(6):742-9. PubMed ID: 10581500
[TBL] [Abstract][Full Text] [Related]
33. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.
Kurth MC; Kurth JH
Am J Med Genet; 1993 Oct; 48(3):166-8. PubMed ID: 8291573
[TBL] [Abstract][Full Text] [Related]
34. [Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson's disease].
Durić G; Svetel M; Nikolaevic SI; Dragadević N; Gavrilović J; Kostić VS
Vojnosanit Pregl; 2007 Jan; 64(1):25-30. PubMed ID: 17304721
[TBL] [Abstract][Full Text] [Related]
35. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients.
Mann A; Miksys SL; Gaedigk A; Kish SJ; Mash DC; Tyndale RF
Neurobiol Aging; 2012 Sep; 33(9):2160-71. PubMed ID: 21958961
[TBL] [Abstract][Full Text] [Related]
36. CYP2D6 allelic frequencies in young-onset Parkinson's disease.
Sandy MS; Armstrong M; Tanner CM; Daly AK; Di Monte DA; Langston JW; Idle JR
Neurology; 1996 Jul; 47(1):225-30. PubMed ID: 8710083
[TBL] [Abstract][Full Text] [Related]
37. Prior history of head trauma in Parkinson's disease.
Factor SA; Weiner WJ
Mov Disord; 1991; 6(3):225-9. PubMed ID: 1922127
[TBL] [Abstract][Full Text] [Related]
38. CYP2D6 polymorphism in Parkinson's disease: the Rotterdam Study.
Harhangi BS; Oostra BA; Heutink P; van Duijn CM; Hofman A; Breteler MM
Mov Disord; 2001 Mar; 16(2):290-3. PubMed ID: 11295783
[TBL] [Abstract][Full Text] [Related]
39. Genetic susceptibility factors for multiple chemical sensitivity revisited.
Berg ND; Rasmussen HB; Linneberg A; Brasch-Andersen C; Fenger M; Dirksen A; Vesterhauge S; Werge T; Elberling J
Int J Hyg Environ Health; 2010 Mar; 213(2):131-9. PubMed ID: 20185366
[TBL] [Abstract][Full Text] [Related]
40. Parkinson's disease, CYP2D6 polymorphism, and age.
Payami H; Lee N; Zareparsi S; Gonzales McNeal M; Camicioli R; Bird TD; Sexton G; Gancher S; Kaye J; Calhoun D; Swanson PD; Nutt J
Neurology; 2001 May; 56(10):1363-70. PubMed ID: 11376189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
